MedTrace Logo

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

NCT02406521 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-04

No results posted yet for this study

Summary

This research study is comparing different drug combinations as a possible treatment for metastatic renal cell carcinoma (mRCC) and bone metastases.

The names of the study interventions involved in this study are:

* Combination of Radium-223 and Sorafenib
* Combination of Radium-223 and Pazopanib

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Pazopanib

DRUG

Sorafenib

DRUG

Radium-223

Sponsors & Collaborators

Principal Investigators

  • Mark Pomerantz, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-12-31
Completion
2019-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02406521 on ClinicalTrials.gov